LIPO

Lipella is a pre-revenue clinical-stage biotech whose only meaningful 'revenue' ($536K FY2024) is grant/collaboration income, not a commercial product. The entire equity case rests on two early-stage tacrolimus reformulations — LP-10 (hemorrhagic cystitis) and LP-310 (oral lichen planus, only through a Phase 2a first-cohort readout) — plus preclinical LP-410/LP-50. None are approved, and the MD&A concedes candidates are 'in the early stages of development' with no guarantee of trials succeeding or approval ever arriving. Against $536K of revenue the company posted a -$5.02M net loss, a -935% net margin and burned -$3.95M in operating cash. That is the definition of a business dependent entirely on future capital, not on its own economics.

The balance sheet cannot carry the plan. FY2024 cash was $2.18M (down 34% YoY) against ~$4M annual cash burn — roughly six months of runway before the period even closes. The auditor's report on the 2024 and 2023 statements carries an explicit going-concern qualification citing recurring losses and an accumulated deficit (-$15.3M retained earnings). Current liabilities nearly doubled (+95.8%) and total liabilities jumped +74.3% while equity fell -39%. The company itself lists as a top risk that it 'may be unable to continue as a going concern' and 'will need to raise additional funding.' Any such raise, at a $331K market cap and a $0.13 share price, means severe, near-guaranteed dilution — the shares are already down 59% in count YoY, consistent with a reverse split and continued issuance, yet the stock still trades as a penny stock.